Latest Conference Articles

Liso-Cel Proves Active Across High-Risk MCL Subgroups

Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

Dr Curran on Developing Strategies for Stage III NSCLC Management

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.